Woodline Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Woodline Partners’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.66M	Hold	200,001	–	–	0.01%	803
2026 Q1	$1.86M	Hold	200,001	–	–	0.01%	812
2025 Q4	$1.5M	Buy	+200,001	New	+$2.03M	0.01%	808
2022 Q1	–	Sell	-132,117	Closed	-$2.9M	–	758
2021 Q4	$2.9M	Buy	132,117 +45,694	+53%	+$1.12M	0.04%	370
2021 Q3	$2.33M	Buy	86,423 +47,715	+123%	+$1.36M	0.04%	389
2021 Q2	$932K	Sell	38,708 -47,121	-55%	-$1.44M	0.02%	444
2021 Q1	$3.72M	Sell	85,829 -17,624	-17%	-$781K	0.08%	222
2020 Q4	$4.29M	Buy	+103,453	New	+$4.27M	0.11%	163

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Woodline Partners's FDMT Position: Q2 2026 in Review

Woodline Partners held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 200,001 shares worth $2.66M. The position accounts for 0.01% of the portfolio, ranked #803.

Woodline Partners first reported a position in FDMT in Q4 2020 and has held it in 8 quarters since. The position peaked at $4.29M in Q4 2020. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Woodline Partners held 200,001 shares of 4D Molecular Therapeutics worth $2.66M as of Q2 2026.
Woodline Partners left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
4D Molecular Therapeutics made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #803 holding.
Woodline Partners first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 8 quarters since.
Woodline Partners's 4D Molecular Therapeutics position peaked at $4.29M in Q4 2020.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.